The Global Autoimmune Disorder Drug Delivery Devices Market is projected to grow at a CAGR of 16.89% during the forecast period, 2022-27, says MarkNtel Advisors in their recent research report. The rising exposure to viruses, bacteria, and dietary inadequacies, among many others, have resulted in the development of autoimmune diseases such as type 1 diabetes, multiple sclerosis, pernicious anemia, etc. According, to the World Economic Forum, the increasing consumption of fast-food diets, which lack nutritious fibers, vitamins, etc., severely affects a person’s gut health. This has largely contributed to an increase in autoimmune disease burden across the globe & has notably contributed to the rising fatality rates. This significantly increased the demand for autoimmune drug devices from both hospitals & homecare to cure various ailments.
Furthermore, the increasing consciousness among the regional governments about the health dangers associated with autoimmune illnesses fuels the market for drug delivery devices. The regional governments & medical practitioners are co-jointly working to achieve the goal of improving therapeutic success to improve the quality of life of their residents & manage the increasing fatality rates across the world. This led to an increase in the demand for autoimmune disorder drug delivery devices in hospitals & health clinics across the world. For instance, the European Union, in 2019, announced funding of USD89.61 million for the development of therapeutic drugs & devices supporting autoimmune disorders.
Moreover, the outbreak of the COVID-19 pandemic had a positive impact on the Autoimmune Disorder Device market, owing to the increasing focus of pharmaceutical companies on providing efficient medical treatment to patients. Furthermore, the discovery of vaccines led to the tremendous demand for such devices across the world, which eventually fueled the market growth. Furthermore, the strategic collaborations among players for the development of niche & effective drugs further propelled the market growth of the Global Autoimmune Drug Delivery Device market.
Prefilled Syringe to Hold a Prominent Share in the Market
Based on product type, the market is segmented into auto-injectors, prefilled syringes, infusion pumps, nebulizers, nasal sprays, and others. Among them, prefilled syringes hold a prominent share in the Autoimmune Drug Delivery Device market on account of the increasing demand for biological drugs & innovation in injectable delivery solutions. The rapid discovery of biological drugs has attracted the attention of key players, as they target diseases that had very limited or no treatment options available. For instance, in April 2021, Genetech announced the U.S FDA approval of its supplemental biologics license application for Xolair prefilled syringe. Similarly, in August 2019, Regeneron Pharmaceuticals announced the approval of the EYELEA (aflibercept) injection prefilled syringe, which is the only anti-VEGF injection for treating four retinal conditions.
North America to Acquire a Significant Share in the Market
Geographically, the North American region dominates the Autoimmune Disorder Drug Delivery Devices market due to the presence of large pharmaceutical companies and the rising number of research & development in the region. Moreover, the growing prevalence of chronic ailments in the region is further driving the market for drug delivery devices. According to the Centers for Disease Control and Prevention, more than 1.6 million people are diagnosed with cancer each year in the United States. In addition, the strong base of healthcare facilities and the growing investments from key players also spurred the market for drug delivery devices for autoimmune disorders.
Furthermore, the rising adoption of self-injectable devices to treat disorders such as diabetes, etc., has increased the growth of the Autoimmune Disorder Drug Delivery Devices market across North America, reveals MarkNtel Advisors in their research report, "Global Autoimmune Disorder Drug Delivery Devices Market Analysis, 2022-2027."
According to MarkNtel Advisors, the leading players in the Global Autoimmune Disorder Drug Delivery Devices Market are Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., The Merck Group, Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB Pharma SA, others.
Key Questions Answered in the Study